PE20211859A1 - Composiciones y metodos para aumentar o mejorar la transduccion de vectores de terapia genetica y para eliminar o reducir las inmunoglobulinas - Google Patents
Composiciones y metodos para aumentar o mejorar la transduccion de vectores de terapia genetica y para eliminar o reducir las inmunoglobulinasInfo
- Publication number
- PE20211859A1 PE20211859A1 PE2021000066A PE2021000066A PE20211859A1 PE 20211859 A1 PE20211859 A1 PE 20211859A1 PE 2021000066 A PE2021000066 A PE 2021000066A PE 2021000066 A PE2021000066 A PE 2021000066A PE 20211859 A1 PE20211859 A1 PE 20211859A1
- Authority
- PE
- Peru
- Prior art keywords
- vector
- enzymes
- recombinant aav
- aav vector
- immunoglobulins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2201—Streptopain (3.4.22.10)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
La presente invencion se refiere a enzimas polipeptidicas que degradan inmunoglobulina G, las cuales comprenden las secuencias de cualquiera de las SEQ ID NO: 3-18, 23 o 48; dichas enzimas son utiles en la prevencion o el tratamiento de una respuesta inmune humoral causada por la administracion de un vector de virus adenoasociado (AAV) recombinante, en donde la respuesta inmune humoral es contra el vector de AAV recombinante y/o un polinucleotido heterologo o una proteina o peptido codificado por un polinucleotido heterologo encapsidado por el vector de AAV recombinante. Tambien se refiere a secuencias de acido nucleico, vector de expresion y un kit que comprende (a) el vector AAV recombinante y (b) la enzima polipeptidica que degrada inmunoglobulina G. Las enzimas de la invencion se aplican en el tratamiento de pacientes que pueden desarrollar o que ya tienen anticuerpos neutralizantes preexistentes de terapia genica de enfermedades tratadas por vector AAV recombinante.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18305971 | 2018-07-17 | ||
US201862768731P | 2018-11-16 | 2018-11-16 | |
PCT/EP2019/069280 WO2020016318A1 (en) | 2018-07-17 | 2019-07-17 | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211859A1 true PE20211859A1 (es) | 2021-09-21 |
Family
ID=67303476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000066A PE20211859A1 (es) | 2018-07-17 | 2019-07-17 | Composiciones y metodos para aumentar o mejorar la transduccion de vectores de terapia genetica y para eliminar o reducir las inmunoglobulinas |
Country Status (26)
Country | Link |
---|---|
US (3) | US20210228738A1 (es) |
EP (2) | EP4154904A1 (es) |
JP (2) | JP2021529821A (es) |
KR (1) | KR20210042308A (es) |
CN (1) | CN112689515A (es) |
AU (1) | AU2019306121A1 (es) |
BR (1) | BR112021000807A8 (es) |
CA (1) | CA3106368A1 (es) |
CL (1) | CL2021000112A1 (es) |
CO (1) | CO2021000326A2 (es) |
DK (1) | DK3768304T3 (es) |
ES (1) | ES2935970T3 (es) |
FI (1) | FI3768304T3 (es) |
HR (1) | HRP20221542T1 (es) |
HU (1) | HUE060720T2 (es) |
IL (1) | IL280099A (es) |
LT (1) | LT3768304T (es) |
MX (1) | MX2021000580A (es) |
PE (1) | PE20211859A1 (es) |
PH (1) | PH12021550115A1 (es) |
PL (1) | PL3768304T3 (es) |
RS (1) | RS63878B1 (es) |
SG (1) | SG11202100306VA (es) |
SI (1) | SI3768304T1 (es) |
WO (1) | WO2020016318A1 (es) |
ZA (1) | ZA202100202B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
BR112020020266A2 (pt) | 2018-04-03 | 2021-01-19 | Stridebio, Inc. | Vetores de vírus com evasão de anticorpos |
TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
US20200165608A1 (en) * | 2018-11-23 | 2020-05-28 | Florida State University Research Foundation, Inc. | Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions |
CN114732822B (zh) * | 2019-03-13 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
CA3133453A1 (en) | 2019-03-21 | 2020-09-24 | Daniel Mccoy | Recombinant adeno-associated virus vectors |
AR118928A1 (es) * | 2019-05-14 | 2021-11-10 | Biomarin Pharm Inc | Métodos de redosificación de vectores de terapia génica |
WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
BR112022006530A2 (pt) | 2019-10-17 | 2022-07-05 | Stridebio Inc | Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c |
WO2021112925A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
AU2021213956A1 (en) | 2020-01-28 | 2022-08-25 | Freeline Therapeutics Limited | Improved assay for determining neutralising antibody titre to a viral vector |
CA3164714A1 (en) | 2020-02-14 | 2021-08-19 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating cdkl5 deficiency disorder |
CN111621506B (zh) * | 2020-05-09 | 2021-07-30 | 华中农业大学 | 牛支原体分泌蛋白MbovP0145及其应用 |
GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
RU2020122141A (ru) * | 2020-07-03 | 2022-01-04 | Максим Петрович Никитин | Способ и композиция на основе генотерапевтического агента и антитела, связывающегося с клетками крови |
WO2022067080A1 (en) * | 2020-09-28 | 2022-03-31 | Scout Bio, Inc. | Composition and uses thereof |
CA3195177A1 (en) | 2020-10-07 | 2022-04-14 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i) |
US20240150752A1 (en) * | 2021-03-09 | 2024-05-09 | The Board Of Regents Of The University Of Texas System | Methods and compositions for mutagenesis screening in mammalian cells |
CA3216491A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
WO2023280175A1 (en) * | 2021-07-06 | 2023-01-12 | National Institute Of Biological Sciences, Beijing | Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis |
WO2023019168A1 (en) | 2021-08-11 | 2023-02-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
EP4349365A1 (en) * | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
CN115558021B (zh) * | 2022-12-01 | 2023-03-17 | 山东大学 | 一种转录因子、重组细胞及其在制备肿瘤治疗药物的应用 |
CN116425873B (zh) * | 2023-06-02 | 2023-09-05 | 苏州百道医疗科技有限公司 | 一种抗ck6重组兔单克隆抗体及其应用 |
CN117126270B (zh) * | 2023-10-25 | 2024-02-13 | 首都儿科研究所 | 一种2型人博卡病毒型别特异性抗体及其应用 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139A (en) | 1847-06-05 | Cajsfkles | ||
US941A (en) | 1838-09-22 | Machine for sawing shingles and staves | ||
US414A (en) | 1837-09-28 | Moetise-latch foe | ||
US5173A (en) | 1847-06-26 | Machinery for | ||
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
WO1995005864A1 (en) | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US6579520B2 (en) | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
US6569645B2 (en) | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
EP1664316B1 (en) | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
EP1781593B1 (en) | 2004-06-07 | 2011-12-14 | Protiva Biotherapeutics Inc. | Cationic lipids and methods of use |
CA2611646C (en) * | 2005-06-09 | 2015-08-11 | Hansa Medical Ab | Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
AU2007303205A1 (en) | 2006-10-03 | 2008-04-10 | Tekmira Pharmaceuticals Corporation | Lipid containing formulations |
US7649243B2 (en) | 2006-11-06 | 2010-01-19 | International Business Machines Corporation | Semiconductor structures incorporating multiple crystallographic planes and methods for fabrication thereof |
GB0624874D0 (en) | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
WO2009064696A1 (en) | 2007-11-14 | 2009-05-22 | The Regents Of The University Of California | Sterol-modified amphiphilic lipids |
EP2350043B9 (en) | 2008-10-09 | 2014-08-20 | TEKMIRA Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010054384A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Lipids and compositions for the delivery of therapeutics |
KR102264822B1 (ko) | 2008-11-10 | 2021-06-14 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
EP2569276B1 (en) | 2010-05-12 | 2021-02-24 | Arbutus Biopharma Corporation | Novel cationic lipids and methods of use thereof |
US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
GB201103780D0 (en) | 2011-03-04 | 2011-04-20 | Hansa Medical Ab | Treatment for ige-mediated disease |
US9169299B2 (en) | 2011-08-24 | 2015-10-27 | The Board Of Trustees Of The Leleand Stanford Junior University | AAV capsid proteins for nucleic acid transfer |
US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
GB201201314D0 (en) * | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
WO2013126803A1 (en) | 2012-02-24 | 2013-08-29 | Protiva Biotherapeutics Inc. | Trialkyl cationic lipids and methods of use thereof |
IN2014DN08812A (es) | 2012-04-18 | 2015-05-22 | Philadelphia Children Hospital | |
TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
RU2625771C2 (ru) | 2012-05-23 | 2017-07-18 | Дженентек, Инк. | Способ отбора терапевтических средств |
US11408899B2 (en) | 2013-07-12 | 2022-08-09 | The Children's Hospital Of Philadelphia | AAV vector and assay for anti-AAV (adeno-associated virus) neutralizing antibodies |
KR102380265B1 (ko) | 2013-07-22 | 2022-03-29 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
KR20180095098A (ko) * | 2016-01-11 | 2018-08-24 | 루비우스 테라퓨틱스, 아이엔씨. | 암 적응증에 대한 다중양식 치료 세포 시스템과 관련된 조성물 및 방법 |
CN109311951B (zh) | 2016-02-04 | 2022-10-11 | 杰诺维斯公司 | 新型链球菌蛋白酶 |
WO2018093868A1 (en) | 2016-11-16 | 2018-05-24 | University Of Florida Research Foundation, Inc. | Immunoglobulin proteases, compositions, and uses thereof |
AU2017378191A1 (en) | 2016-12-16 | 2019-07-04 | Uniqure Ip B.V. | Immunoadsorption |
EP3589311A1 (en) | 2017-03-02 | 2020-01-08 | Genethon | Method for removing anti-aav antibodies from a blood-derived composition |
US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
-
2017
- 2017-07-17 US US17/050,911 patent/US20210228738A1/en not_active Abandoned
-
2019
- 2019-07-17 KR KR1020217001502A patent/KR20210042308A/ko active Search and Examination
- 2019-07-17 SI SI201930426T patent/SI3768304T1/sl unknown
- 2019-07-17 ES ES19740384T patent/ES2935970T3/es active Active
- 2019-07-17 BR BR112021000807A patent/BR112021000807A8/pt unknown
- 2019-07-17 CN CN201980048115.9A patent/CN112689515A/zh active Pending
- 2019-07-17 AU AU2019306121A patent/AU2019306121A1/en active Pending
- 2019-07-17 EP EP22198839.7A patent/EP4154904A1/en active Pending
- 2019-07-17 LT LTEPPCT/EP2019/069280T patent/LT3768304T/lt unknown
- 2019-07-17 JP JP2021502435A patent/JP2021529821A/ja active Pending
- 2019-07-17 RS RS20221191A patent/RS63878B1/sr unknown
- 2019-07-17 MX MX2021000580A patent/MX2021000580A/es unknown
- 2019-07-17 PE PE2021000066A patent/PE20211859A1/es unknown
- 2019-07-17 EP EP19740384.3A patent/EP3768304B1/en active Active
- 2019-07-17 HU HUE19740384A patent/HUE060720T2/hu unknown
- 2019-07-17 SG SG11202100306VA patent/SG11202100306VA/en unknown
- 2019-07-17 DK DK19740384.3T patent/DK3768304T3/da active
- 2019-07-17 PL PL19740384.3T patent/PL3768304T3/pl unknown
- 2019-07-17 FI FIEP19740384.3T patent/FI3768304T3/fi active
- 2019-07-17 CA CA3106368A patent/CA3106368A1/en active Pending
- 2019-07-17 WO PCT/EP2019/069280 patent/WO2020016318A1/en active Application Filing
- 2019-07-17 HR HRP20221542TT patent/HRP20221542T1/hr unknown
-
2021
- 2021-01-11 IL IL280099A patent/IL280099A/en unknown
- 2021-01-12 ZA ZA2021/00202A patent/ZA202100202B/en unknown
- 2021-01-14 CL CL2021000112A patent/CL2021000112A1/es unknown
- 2021-01-15 CO CONC2021/0000326A patent/CO2021000326A2/es unknown
- 2021-01-15 PH PH12021550115A patent/PH12021550115A1/en unknown
- 2021-04-07 US US17/224,367 patent/US20210246469A1/en not_active Abandoned
-
2022
- 2022-07-12 US US17/862,622 patent/US20230142731A1/en active Pending
-
2024
- 2024-03-27 JP JP2024051529A patent/JP2024075765A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3106368A1 (en) | 2020-01-23 |
RS63878B1 (sr) | 2023-02-28 |
CL2021000112A1 (es) | 2021-09-03 |
HUE060720T2 (hu) | 2023-04-28 |
LT3768304T (lt) | 2023-03-27 |
BR112021000807A8 (pt) | 2022-12-06 |
IL280099A (en) | 2021-03-01 |
CN112689515A (zh) | 2021-04-20 |
AU2019306121A1 (en) | 2021-01-28 |
CO2021000326A2 (es) | 2021-04-19 |
HRP20221542T1 (hr) | 2023-02-17 |
JP2024075765A (ja) | 2024-06-04 |
US20210246469A1 (en) | 2021-08-12 |
EP3768304B1 (en) | 2022-10-12 |
SG11202100306VA (en) | 2021-02-25 |
PL3768304T3 (pl) | 2023-03-13 |
US20230142731A1 (en) | 2023-05-11 |
DK3768304T3 (da) | 2023-01-09 |
ES2935970T3 (es) | 2023-03-13 |
US20210228738A1 (en) | 2021-07-29 |
SI3768304T1 (sl) | 2023-02-28 |
PH12021550115A1 (en) | 2021-10-04 |
EP4154904A1 (en) | 2023-03-29 |
MX2021000580A (es) | 2021-07-15 |
BR112021000807A2 (pt) | 2021-05-11 |
JP2021529821A (ja) | 2021-11-04 |
ZA202100202B (en) | 2022-01-26 |
KR20210042308A (ko) | 2021-04-19 |
FI3768304T3 (fi) | 2023-01-13 |
EP3768304A1 (en) | 2021-01-27 |
WO2020016318A1 (en) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211859A1 (es) | Composiciones y metodos para aumentar o mejorar la transduccion de vectores de terapia genetica y para eliminar o reducir las inmunoglobulinas | |
Lustigman et al. | Molecular cloning and characterization of onchocystatin, a cysteine proteinase inhibitor of Onchocerca volvulus. | |
WO2018226861A4 (en) | COMPOSITIONS AND METHODS FOR INTERNALIZATION OF ENZYMES | |
JP2020523321A5 (es) | ||
PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
JP2021508235A5 (es) | ||
PE20191261A1 (es) | Composiciones utiles para el tratamiento de atrofia muscular espinal | |
MX2021015753A (es) | Constructo de arn. | |
PE20220930A1 (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica | |
MX2018010850A (es) | Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos. | |
PH12021551135A1 (en) | Rna encoding a protein | |
RU2007140978A (ru) | Пассивная иммунизационная терапия на основе пептидов для лечения атеросклероза | |
JP2014510519A5 (es) | ||
JP2017513849A5 (es) | ||
MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
George et al. | Functional characterization of recombinant bromelain of Ananas comosus expressed in a prokaryotic system | |
WO2020102740A3 (en) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins | |
Bissonnette et al. | Proteomic analysis and immunodetection of the bovine milk osteopontin isoforms | |
EA201990856A1 (ru) | Новые противомикробные агенты против бактерий enterococcus | |
WO2021087296A8 (en) | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | |
PE20210918A1 (es) | Composiciones y metodos para el tratamiento de la distrofia macular | |
RU2020106669A (ru) | Синтетические белки и пути их терапевтического применения | |
JP5055522B2 (ja) | 多包条虫由来の新規蛋白質 | |
RU2020115161A (ru) | Днк моноклональных антител против ctla-4 для лечения и профилактики рака |